Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Crispr Therapeutics (NASDAQ: CRSP) is a fascinating growth stock that I’ve been watching for a few years now. In early 2021 ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...